Aktuelle Strategien zur Systemtherapie des frühen Mammakarzinoms von der 18. Internationalen St.-Gallen-Konsensuskonferenz

AGO Kommission Mamma Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome (März 2023). https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2023/AGO_2023D_Gesamtdatei.pdf. Zugegriffen: 3. Apr. 2023

Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816

Díaz-Roldán J, Eguía-Larrea M, Rubio-Sánchez T et al (2022) Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease? Breast Cancer 29(1):9–18

Domchek SM, Postel-Vinay S, Im S‑A et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21(9):1155–1164

Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446

Gluz O, Nitz U, Christgen M (2022) Impact of age, recurrence score and ovarian function suppression on endocrine response to short preoperative endocrine therapy: analysis of ADAPT and ADAPTcycle trials. Ann Oncol 33(suppl_7):S808–S869

Gnant M, Fitzal F, Rinnerthaler G et al (2021) Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med 385(5):395–405

Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219

Gray RG, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. JCO 31(18_suppl):5

Harbeck N, Rastogi P, Martin M et al (2021) Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 32(12):1571–1581

Johnston SRD, Harbeck N, Hegg R et al (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38(34):3987–3998

Kalinsky K, Barlow WE, Gralow JR et al (2021) 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336–2347

Konstantinopoulos PA, Waggoner S, Vidal GA et al (2019) Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 5(8):1141–1149

Loibl S, Jackisch C, Rastogi P et al (2019) GeparDouze/NSABP B‑59: a randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with Triple Negative Breast Cancer (TNBC) followed by adjuvant atezolizumab or placebo. Ann Oncol 30:iii38

Loibl S, Huang C‑S, Mano MS et al (2022) Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. NPJ Breast Cancer 8(1):106

Loibl S, Schneeweiss A, Huober J et al (2022) Neoadjuvant durvalumab improves survival in early Triple-Negative Breast Cancer independent of pathological complete response. Ann Oncol 33(11):1149–1158

Loibl S, Jassem J, Sonnenblick A et al (2022) VP6-2022: adjuvant pertuzumab and trastuzumab in patients with early HER‑2 positive breast cancer in APHINITY: 8.4 years’ follow-up. Ann Oncol 33(9):986–987

Nelson DR, Brown J, Morikawa A et al (2022) Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS ONE 17(2):e264637

Nitz UA, Gluz O, Kümmel S et al (2022) Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2− early breast cancer. J Clin Oncol 40(23):2557–2567

O’Shaughnessy J, Rastogi P, Harbeck N (2021) Adjuvant abemaciclib combined with endo-crine therapy: updated results from monarchE. ESMO Virutal Plenary Session, October 14, 2021

Pan H, Gray R, Braybrooke J et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846

Park-Simon T, Müller V, Jackisch C et al (2023) AGO recommendations for the diagnosis and treatment of patients with Early Breast Cancer (EBC): update 2023. Breast Care 18(4):288–304. https://doi.org/10.1159/000531578

Partridge AH, Niman SM, Ruggeri M et al (2023) Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med 388(18):1645–1656

Piccart M, van ’t Veer LJ, Poncet C et al (2021) 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 22(4):476–488

Reinisch M, Seiler S, Hauzenberger T et al (2021) Efficacy of endocrine therapy for the treatment of breast cancer in men: results from the MALE phase 2 randomized clinical trial. JAMA Oncol 7(4):565–572

Rugo HS, Llombart-Cussac A, Andre F et al (2020) KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC). J Clin Oncol 38(15_suppl):TPS596–TPS596

Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early Triple-Negative Breast Cancer. N Engl J Med 382(9):810–821

Schmid P, Cortes J, Dent R et al (2022) Event-free survival with pembrolizumab in early Triple-Negative Breast Cancer. N Engl J Med 386(6):556–567

Smith I, Robertson J, Kilburn L et al (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 21(11):1443–1454

Sparano J, Gray RJ, Makower D (2022) Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates. Abstract no. GS1-05 2022 San Antonio Breast Cancer Symposium

Sparano JA, Gray RJ, Ravdin PM et al (2019) Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380(25):2395–2405

Tarantino P, Tayob N, Dang CT (2022) Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I HER2+ breast cancer: 5‑year results and correlative analyses from ATEMPT (TBCRC033). Abstract no. PD18-01 2022 San Antonio Breast Cancer Symposium

Tolaney SM, Tarantino P, Graham N et al (2023) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 24(3):273–285

Tung NM, Robson ME, Ventz S et al (2020) TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 38(36):4274–4282

Tutt A, Garber JE, Kaufman B et al (2021) OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. J Clin Oncol 39(18_suppl):LBA1–LBA1

Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant olaparib for patients with BRCA1− or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394–2405

Yadav S, Hu C, Hart SN et al (2020) Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol 38(13):1409–1418

Yadav S (2022) Population-based estimates of contralateral breast cancer risk among carriers of Germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2. Abstract no. GS4-04 2022 San Antonio Breast Cancer Symposium